

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
July 17, 2025

MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

LaToya Bonner, PharmD, MBA

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

William J. Gradishar, MD

Betsy Bramsen Professor of Breast Oncology &
Professor of Medicine
Deputy Director, Clinical Network
Director, Maggie Daley Center for Women's
Cancer Care
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

Daniel Spratt, MD

Associate Chief Scientific Officer, University
Hospitals Cleveland Medical Center
Medical Director, Clinical Research Center
Vincent K Smith Chair of Radiation Oncology
UH Seidman Cancer Center
Chair, Department of Radiation Oncology
Professor, Departments of Radiation Oncology and
Urology
Case Western Reserve University
Cleveland, Ohio

Neil Vasan, MD, PhD

(Acting Chairperson)

Director, Breast Cancer Translational Research
Assistant Professor
Department of Medicine, NYU Grossman School
of Medicine
Perlmutter Cancer Center, NYU Langone Health
New York, New York

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Tara L. Frenkl, MD, MPH

(Industry Representative)

Senior Vice President, Head of Global Medical
Strategy and Evidence Generation
Bayer Pharmaceuticals
Whippany, New Jersey

TEMPORARY MEMBERS (Voting)

Paul Beringer, PharmD

Professor of Clinical Pharmacy
USC Alfred E. Mann School of Pharmacy and
Pharmaceutical Sciences
University of Southern California
Los Angeles, California

Mark R. Conaway, PhD

Professor, Division of Translational Research and
Applied Statistics
Department of Public Health Sciences
The University of Virginia School of Medicine
Charlottesville, Virginia

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
July 17, 2025

MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting) (cont.)

John DeFlice, MD

(Patient Representative)

Gastroenterologist, Retired

Albuquerque, New Mexico

Ravi A. Madan, MD

Senior Clinician

Head, Prostate Cancer Clinical Research Section

Genitourinary Malignancies Branch

Center for Cancer Research

National Cancer Institute

National Institutes of Health (NIH)

Bethesda, Maryland

Grzegorz (Greg) S. Nowakowski, MD, FASCO

Professor of Medicine and Oncology

Enterprise Deputy Director for Clinical Research

Mayo Clinic Comprehensive Cancer Center

Chair, Lymphoid Malignancy Group

Vice-Chair, Division of Hematology

Mayo Clinic

Rochester, Minnesota

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

Director

Oncology Center of Excellence (OCE), FDA

Director (Acting)

Office of Oncologic Diseases (OOD)

Office of New Drugs (OND), CDER, FDA

Nicole Gormley, MD

Director

Division of Hematologic Malignancies II (DHM II)

OOD, OND, CDER, FDA

Nicholas Richardson, DO, MPH

Deputy Director

DHM II, OOD, OND, CDER, FDA

Bindu Kanapuru, MD

Supervisory Associate Director for Therapeutic

Review

DHM II, OOD, OND, CDER, FDA

Deepti Telaraja, MD

Clinical Team Leader (Acting)

DHM II, OOD, OND, CDER, FDA

Andrea Baines, MD, PhD

Clinical Reviewer

DHM II, OOD, OND, CDER, FDA